Australian Basic Materials Stock News

Key Insights Using the 2 Stage Free Cash Flow to Equity, NRW Holdings fair value estimate is AU$8.94 Current share...

Australian shares are poised for a robust start, with a projected 0.75% increase following the Federal Reserve's decision to trim U.S. rates for the third consecutive time. In this context, penny stocks—despite their somewhat outdated moniker—remain an intriguing investment area due to their potential for significant returns when backed by solid financials. This article explores three ASX penny stocks that exhibit strong financial foundations and could offer investors hidden value and growth...

With its stock down 16% over the past three months, it is easy to disregard Objective (ASX:OCL). But if you pay close...

Hazer Group Limited ( ASX:HZR ) shareholders should be happy to see the share price up 12% in the last quarter. But...

SGH Limited ( ASX:SGH ) received a lot of attention from a substantial price movement on the ASX over the last few...

With a price-to-sales (or "P/S") ratio of 3.3x Raiz Invest Limited ( ASX:RZI ) may be sending very bullish signals at...

When close to half the companies operating in the Consumer Services industry in Australia have price-to-sales ratios...

We wouldn't blame Catalyst Metals Limited ( ASX:CYL ) shareholders if they were a little worried about the fact that...

Most readers would already be aware that Whitehaven Coal's (ASX:WHC) stock increased significantly by 21% over the past...

Key Insights Tesoro Gold's significant individual investors ownership suggests that the key decisions are influenced by...

Clinuvel Pharmaceuticals (ASX:CUV) is in the spotlight after unveiling a major expansion of its Vallaurix innovation hub in Singapore. The company has announced a five year push backed by the Economic Development Board to accelerate advanced peptide drug development. See our latest analysis for Clinuvel Pharmaceuticals. The market seems to be warming to that strategy, with a 30 day share price return of 17.15% and a 90 day gain of 21.11%. However, the five year total shareholder return...

Champion Iron's (ASX:CIA) stock is up by a considerable 35% over the past three months. However, we wonder if the...

Some Kip McGrath Education Centres Limited ( ASX:KME ) shareholders may be a little concerned to see that insider Storm...

Insiders who bought Cryosite Limited ( ASX:CTE ) in the last 12 months may probably not pay attention to the stock's...

Key Insights The considerable ownership by individual investors in Prospect Resources indicates that they collectively...

Anyone interested in Imdex Limited ( ASX:IMD ) should probably be aware that the Independent Non-Executive Chairman...

Investors may wish to note that the Non Executive Independent Chairman of Beforepay Group Limited , Brian Hartzer...

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

As the Australian market experiences a mixed performance with materials leading and IT and industrials lagging, investors are keenly observing sector shifts. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials.

In recent days, Iluka Resources withdrew its 2025 synthetic rutile production guidance due to uncertainty over a key UK customer agreement, prompting analyst downgrades and highlighting ongoing operational and market disruptions affecting its mineral sands and rare earths business. This shift draws attention to how sensitive Iluka’s outlook is to individual customer contracts, production reliability, and evolving tariffs and export controls in its core markets. We’ll now examine how the...

Mesoblast (ASX:MSB) steps into the spotlight this week as CEO Silviu Itescu presents at the Piper Sandler 37th Annual Healthcare Conference, and traders are watching for fresh color on strategy and late stage trials. See our latest analysis for Mesoblast. That anticipation has arrived on the back of a strong near term rebound, with a 1 month share price return of 27.03 percent and a 1 year total shareholder return of 65.88 percent, even though the year to date share price return remains...

Immutep (ASX:IMM) has jumped onto investors radar after two meaningful updates: a lucrative licensing deal with Dr. Reddy’s for its cancer immunotherapy efti, and fresh Phase II breast cancer data reinforcing its development pathway. See our latest analysis for Immutep. The recent licensing deal and upbeat breast cancer data appear to have flipped sentiment, with a 1 month share price return of 25.49 percent and a 90 day share price return of 36.17 percent standing in contrast to a still...

Elevra Lithium, formed from Sayona Mining’s acquisition of Piedmont Lithium, recently reported record production at its North American Lithium mine and outlined a brownfield expansion aimed at lifting output and lowering operating costs. The expiry and cessation of nearly 14,900 unexercised options subtly reshapes Elevra Lithium’s capital structure, highlighting management’s focus on operational performance over equity dilution. With those developments in mind, we’ll explore how record North...

In late November 2025, APA Group announced a special call to discuss its Joint Development Agreement with CS Energy to develop and own the proposed Brigalow Peaking Power Plant. This collaboration highlights APA Group’s push further into peaking power generation, potentially enhancing its role in supporting grid reliability alongside renewables. We’ll now explore how the Brigalow peaking power partnership with CS Energy may reshape APA Group’s existing investment narrative and risk...